Ultragenyx wins first FDA nod for gene therapy targeting rare metabolic disease

The FDA granted accelerated approval to Ultragenyx's gene therapy for an ultra-rare glycogen storage disorder that can trigger dangerous drops in blood sugar. This marks the company's first approved gene therapy. The decision provides a new treatment option for patients with limited existing therapies.

The approval marks a significant milestone for Ultragenyx, which had not previously brought a gene therapy to market. The treatment targets an ultra-rare glycogen storage disorder, a condition where the body struggles to regulate sugar storage, potentially leading to severe hypoglycemic episodes. Because the patient population is small and existing options are sparse, the therapy addresses a clear unmet medical need.

Regulators granted the therapy accelerated approval, a pathway used when a drug shows promise for serious conditions based on surrogate endpoints. This decision adds a novel, one-time treatment approach to a field historically reliant on dietary management and symptomatic care. For patients and families navigating this disorder, the approval introduces a new therapeutic avenue where few have existed.